Skip to content
OpenCapital
Get started

4D Molecular Therapeutics FDMT Q3 2025 earnings

Reported November 10, 2025 · Before market open

Revenue$90.0KMiss by $30.8M
EPS-$1.01Beat by $0.01
Revenue estimate$30.9M
EPS estimate-$1.02

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$3.7M
EPS estimate-$1.04

Financials

Q3 2025

Income statement

See full
Revenue$90.0K+2,900%
Operating income-$61.2M-19.7%
Net income-$56.9M-29.7%
EPS (diluted)-$1.01-27.8%

Balance sheet

See full
Cash & equivalents$48.6M-74.1%
Total debt$22.3M-10.4%
Total equity$369.0M-33.3%
Total assets$424.0M-29.8%

Cash flow

See full
Operating cash flow-$46.5M-58.2%
Free cash flow-$46.4M-48.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$405.84M-32.1%
Enterprise value$379.55M-12.7%
P/S3,382×-13,218×

Profitability

See full
Operating margin-191,982.5%-71,203pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.1×0.0×
Current ratio8.4×-8.9×

Segments

By product

See full
Collaboration And License Revenue$90.0K+2,900%

Versus estimates

Revenue

Q1 2026$3.0MBeat by $459.5KQ4 2025$85.1MBeat by $58.1M
Q3 2025$90.0KMiss by $30.8M
Q2 2025$15.0KBeat by $10.3KQ1 2025$14.0KMiss by $523.5KQ4 2024$1.0KMiss by $2.3M

Diluted EPS

Q1 2026-$1.01Miss by $0.04Q4 2025$0.43Beat by $0.96
Q3 2025-$1.01Beat by $0.01
Q2 2025-$0.98Miss by $0.10Q1 2025-$0.86Miss by $0.02Q4 2024-$0.90Miss by $0.10

Ask the moment 4D Molecular Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did 4D Molecular Therapeutics report Q3 2025 earnings?
4D Molecular Therapeutics (FDMT) reported Q3 2025 earnings on November 10, 2025 before market open.
What were 4D Molecular Therapeutics's Q3 2025 revenue and EPS?
4D Molecular Therapeutics reported revenue of $90.0K and eps of $-1.01 for Q3 2025.
Did 4D Molecular Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $30.9M by $30.8M. EPS beat the consensus estimate of $-1.02 by $0.01.
How did 4D Molecular Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2900.0% from $3.0K a year earlier and eps declined 27.8% from $-0.79.
Where can I find 4D Molecular Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-272286) and the 10-Q periodic report (0001193125-25-273343) directly on SEC EDGAR. The filing index links above go to sec.gov.